Sign in

Pablo Angeles Tacchino

@pabloangelest.bsky.social
219 followers 317 following 24 posts

Médico Nefrólogo

PostsRepliesMedia
Reposted by Pablo Angeles Tacchino
Rolando Claure @runningkidneys.bsky.social · 29/07/2026
Urea may be a cost-effective alternative to tolvaptan for 🏥 SIADH patients. In a retrospective 📑 (n=537) both achieved similar correction of HypoNa (>130 mmol/L) while tolvaptan acted faster but caused more overcorrection & was substantially more 💵 🔗https://doi.org/10.1093/ndt/gfag165
doi.org
Urea vs. tolvaptan for hospitalized patients with SIADH
AbstractRationale. Hyponatremia is the most common electrolyte disorder found in hospitalized patients and is associated with an increased mortality. Urea
044
Reposted by Pablo Angeles Tacchino
Priscilla Smith @priscillasmith.bsky.social · 31/07/2026
Thanks for the plug @hswapnil.medsky.social definitely want to see the big beet trial happen - might need some crowdfunding though.
032
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 31/07/2026
Guidance on nutrition supplementation in dialysis www.kireports.org/article/S246... In @kireports.bsky.social Increasing protein intake once dialysis begins is important!
Algorithm
1119
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/06/2026
The NDT paper is too small and underpowered to say much - I would be careful denying effective therapies just based on BMI? Yes - this applies to GLP1RAs especially as we head into malnourishment - but I would be careful about not extrapolating too much and being unnecessarily nihilistic! #ERA26
121
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/06/2026
And FIND CKD is live already on NEJM www.nejm.org/doi/full/10.... #ERA26
nejm.org
Finerenone in Persons with Chronic Kidney Disease without Diabetes | NEJM
In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD)...
2167
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/06/2026
Another #ERA26 simulpub Effect of empa/finerenone on BP, yet another splice from CONFIDENCE www.ahajournals.org/doi/10.1161/... (If you want a BP effect, use Spiro)
ahajournals.org
Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure | Hypertension
BACKGROUND: This secondary analysis of the CONFIDENCE (combination effect of fInerenone and empagliflozin in participants with chronic kidney disease and type 2 diabetes using a UACR endpoint) trial…
052
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/06/2026
And the GN subgroup from FIND CKD Again somewhat underwhelming but small and significant benefit jamanetwork.com/journals/jam... in JAMA #ERA26
jamanetwork.com
Validate User
121
Reposted by Pablo Angeles Tacchino
Juan Carlos Q Vélez, MD @juancarlosqvelez.bsky.social · 05/06/2026
It’s appalling. Many people watched the trial happen and didn’t feel uncomfortable. Do not understand what was FDA’s position on this.
172
Reposted by Pablo Angeles Tacchino
American Journal of Hypertension @amjhypertension.bsky.social · 08/04/2026
#HotOffThePress academic.oup.com/ajh/advance-... Nighttime Central Blood Pressure and Left Ventricular Hypertrophy in Non-Dialysis CKD: A Multicenter Study
VA
034
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 23/02/2026
FDA asks Amgen (which bought Chemocentryx) for voluntary withdrawal of Avacopan From January, with fresh Medscape coverage Amgen www.amgen.com/tavneos-pres... Medscape www.medscape.com/s/viewarticl... - liver concerns - BVAS scoring discrepancy from ADVOCATE
medscape.com
What’s at Issue in the FDA’s Request to Withdraw Avacopan?
European regulators are also conducting a review of avacopan. The issue appears to involve data from the pivotal ADVOCATE trial and questions of liver safety.
2128
Reposted by Pablo Angeles Tacchino
Joel Topf @kidneyboy.bsky.social · 01/04/2026
It's totally insane That article was due to the loophole from the original AKI guidelines that defined AKI solely by the change in creatinine. The fact that they are embracing that hack is absurd.
031
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 01/04/2026
It’s ridiculous!
131
Pablo Angeles Tacchino @pabloangelest.bsky.social · 31/03/2026
I was reading the new KDIGO AKI guideline draft. What concerns me most is this recommendation, probably influenced by the highly criticized NEJM 2024 article @kidneyboy.bsky.social @hswapnil.medsky.social @nephjc.bsky.social @juancarlosqvelez.bsky.social @nephroseeker.medsky.social
274
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 30/03/2026
As expected it doesn’t do much Hyperuricemia is a bystander, not on the causal pathway (so treat only if gout) #ISNWCN
Results
052
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 30/03/2026
Protocol here pubmed.ncbi.nlm.nih.gov/33040002/ Figure 1 is very instructive (trial ran through COVID) #ISNWCN
Figure 1
131
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 30/03/2026
After CKD FiX and PEARL, will lowering uric acid work in PD patients for CV outcomes? #ISNWCN
Title slide
162
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 30/03/2026
One more LBCT, one more CONFIDENCE analysis at #ISNWCN This time in @ndt-era.bsky.social Age and Sex interactions academic.oup.com/ndt/advance-...
Visual abstract
031
Reposted by Pablo Angeles Tacchino
Cristina Popa @nephroseeker.medsky.social · 01/03/2026
It’s March 1st 🌸🌷… So, it’s #NephMadness time Here are the 8 topics competing tuis year 👇👇 Any favourites? ajkdblog.org/2026/03/01/w...
ajkdblog.org
Welcome to #NephMadness 2026
Our beautiful baby has grown into a moody, hormonal teen.  That’s right, it’s year 14 of NephMadness!  Whether this is your first time or you are a seasoned veteran, we have all the inf…
077
Reposted by Pablo Angeles Tacchino
JAMA Network Open @jamanetworkopen.com · 19/02/2026
In #ChronicKidneyDisease, higher urinary protein to creatinine ratio was more strongly associated with increased risk of cognitive impairment than lower eGFR, suggesting the importance of proteinuria in cognitive risk assessment. ja.ma/3OvDzof
Four bar graphs show hazard ratios for cognitive impairments based on UPCR levels and eGFR. Graph A: Impairment in global cognition (3MS). Graph B: Impairment in verbal memory. Graph C: Impairment in attention. Graph D: Impairment in executive function.
054
Reposted by Pablo Angeles Tacchino
Joel Topf @kidneyboy.bsky.social · 14/12/2025
Freely Filtered #87: Can Fish Oil Knock the Crap out of Dialysis Associated CV Disease? We tried to find a problem with PISCES and came up with an empty net. Time to get your supplements on for your dialysis patients! www.nephjc.com/freelyfilter...
nephjc.com
FF 87 Can Fish Oil Knock the Crap out of Dialysis Associated CV Disease? — NephJC
FF 87 Can Fish Oil Knock the Crap out of Dialysis Associated CV Disease?
3196
Reposted by Pablo Angeles Tacchino
Rolando Claure @runningkidneys.bsky.social · 11/11/2025
Great day-by-day recaps of #KidneyWk from the #NephJC team—perfect if you missed a session. Begin here 👉🏻 www.nephjc.com/news/2025/11...
nephjc.com
Kidney Week in Houston: Day 3 — NephJC
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.
051
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 06/11/2025
large cohort study of CDK 4/6 BRAF EGFR VEGF and other cancer treatments #OncoNephrology #NephSky #KidneyWk jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
The subdistribution hazard ratios for progressive kidney dysfunction are shown for each drug group compared with their respective propensity score–matched cohort. The blue dots represent the hazard ratio and 95% CIs. Due to wide confidence intervals, MET inhibitors results reported in the text and not displayed here. MET inhibitors are included in overall treated group. Model is adjusted for hypertension, diabetes, ischemic heart disease, congestive heart failure, chronic obstructive pulmonary disease, cirrhosis, age, sex, race, body mass index, and eGFR before drug start. ALK indicates anaplastic lymphoma kinase; BRAF, B-Raf proto-oncogene, serine/threonine kinase; CDK4/6, cyclin dependent kinase 4 or 6; EGFR, endothelial growth factor receptor; ERBB2, human epidermal growth factor receptor 2; PARP, poly(adenosine diphosphate-ribose) polymerase; VEGFR, vascular endothelial growth factor receptor.
176
Reposted by Pablo Angeles Tacchino
Michelle Rheault, MD @rheaultm.bsky.social · 06/11/2025
Finally, a large group of patients are those with heterozygous COL4A3 and COL4A4 variants who do well long term with only microscopic hematuria. The problem is that you don't know which patients will fall into this bucket and which will fall into the buckets above by genotyping alone. #KidneyWk
073
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/11/2025
Trials coming out already! jamanetwork.com/journals/jam... Rituximab better than placebo in FRNS/SDNS Duh. #KidneyWk #NephSky
Visual abstract
1228
Reposted by Pablo Angeles Tacchino
Nature Reviews Nephrology @natrevneph.nature.com · 29/09/2025
nature.com
A guide to uraemic toxicity
Nature Reviews Nephrology, Published online: 23 September 2025; doi:10.1038/s41581-025-01006-4This Review provides a guide to metabolite retention in kidney disease and includes an overview of key uraemic toxins and the complex mechanisms underlying their toxicity, as well as a discussion of key strategies with the potential to prevent or mitigate their adverse effects.
021
Reposted by Pablo Angeles Tacchino
Joel Topf @kidneyboy.bsky.social · 25/09/2025
Next up Zigakibart in IgAN treated for 76 weeks. Zigakibart is an April inhibitor (learned how to access the poster slides, so screen grabs rather than photos of the slides) Title, methods, and table 1 demographics #GlomCon
295
Reposted by Pablo Angeles Tacchino
Joel Topf @kidneyboy.bsky.social · 26/09/2025
Lionel MEST-C I'm dying #GlomCon #Edgar1ofAKind
084
Reposted by Pablo Angeles Tacchino
Joel Topf @kidneyboy.bsky.social · 26/09/2025
It wouldn't be an @edgarvlermamd.bsky.social lecture without a Spiderman ref #GlomCon
172
Reposted by Pablo Angeles Tacchino
Joel Topf @kidneyboy.bsky.social · 26/09/2025
Fervenza has been asked about galactose deficient IgA1. He says he is going to be nice but then says he has nothing nice to say about KDIGO. He says guidelines are always backward looking. No answer about Gd-IgA1 though #GlomCon
241
Reposted by Pablo Angeles Tacchino
Hemily Zandybell, MD @zandybellnefro.bsky.social · 19/09/2025
👩🏻 75-year-old woman - History of epilepsy 📈 Creatinine: 2.36 → 7.3 mg/dL in 9 days 🧪 Positive MPO ANCA (61.06)
131
Pablo Angeles Tacchino @pabloangelest.bsky.social · 03/09/2025
010
Pablo Angeles Tacchino @pabloangelest.bsky.social · 15/08/2025
After 8 years, a new AHA/ACCA hypertension guideline 📊 Proposes cardiovascular risk assessment using the PREVENT calculator. Urine albumin-to-creatinine ratio in all hypertensive patients. Plasma aldosterone-to-renin ratio to detect hyperaldosteronism.
010
Reposted by Pablo Angeles Tacchino
AIN/Sandipan Shringi @nephrosage.bsky.social · 08/08/2025
HDF over HD: New report from the EuDial working group More info: academic.oup.com/ndt/article/... @ndt-era.bsky.social, @hjanders.bsky.social
022
Reposted by Pablo Angeles Tacchino
Nephrology Journal Club @nephjc.bsky.social · 05/08/2025
HiLo, HiLo it's off to work we go! ⛏️ Join us 9 pm EST 8/5/25 to discuss. #NephJC #NephSky Controlling Phos in patients on HD is a lot of work, but is it worth it? HiLo looks at hospitalization & death in low/high Phos goals. Will we finally have a RCT with answers ⁉️ www.nephjc.com/news/hilo-tr...
nephjc.com
High or Low Phosphate? Are we Missing the (P)oint? — NephJC
This week, we will discuss the phosphate targets in dialysis. Are you aiming for HIgh or Low?
01715
Pablo Angeles Tacchino @pabloangelest.bsky.social · 11/07/2025
so the HiLo study was unremarkable in the treatmet of Hyperphosphahtemia, will the Phosphate trial tell us something different?
010
Reposted by Pablo Angeles Tacchino
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 07/06/2025
The Pathology Lesion Patterns of Podocytopathies: How and why? #ERA25 🇦🇹 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/35281116/
0146
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/06/2025
Hyperkalemia rates not lower with adding a flozin to the MRA 🤔 www.nejm.org/doi/full/10.... #ERA25
Adverse effects
2113
Reposted by Pablo Angeles Tacchino
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/06/2025
The first #ERA25 simultaneous pub CONFIDENCE trial of empagliflozin + finerenone in N = 579 Greater reduction in ACR and BP Note the impressive GFR dip www.nejm.org/doi/full/10....
Urinary Albumin-to-Creatinine Ratio, Serum Potassium Level, Estimated Glomerular Filtration Rate, and Systolic Blood Pressure over Time.
34123
Pablo Angeles Tacchino @pabloangelest.bsky.social · 07/06/2025
010
Reposted by Pablo Angeles Tacchino
Megan Telford @megtelford.bsky.social · 05/06/2025
www.nejm.org/doi/full/10.... Very exciting to hear about this ground breaking clinical trial at #era2025
nejm.org
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | NEJM
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chr...
051
Pablo Angeles Tacchino @pabloangelest.bsky.social · 04/06/2025
#era25 following through social media expectorante the resultado of CONFIDENCE trial.
031
Pablo Angeles Tacchino @pabloangelest.bsky.social · 07/04/2025
In Heart Failure, Finerenone 20-40mg vs placebo, ↓ cardiorenal risks, effect appears to be independient of the renal risk, ↓ albuminuria more Benefit in renal outcome PostHoc of FINEARTS-HF JACC 2025. doi.org/10.1016/j.jc...
000
Pablo Angeles Tacchino @pabloangelest.bsky.social · 17/03/2025
Different guidelines hypertension targets comparisson. HYPERTENSION 2025. #Hypertension
011
Reposted by Pablo Angeles Tacchino
Nayan Arora @captainchloride.bsky.social · 07/03/2025
So maybe we don’t need to hold flozins before surgery after all? jamanetwork.com/journals/jam...
jamanetwork.com
11910
Reposted by Pablo Angeles Tacchino
Brendon Neuen @brendonneuen.bsky.social · 02/03/2025
📢 New CREDENCE data in NDT: SGLT2i in CKD and T2D: ✅ ↓ Insulin initiation/dose intensification by 19% ✅ ↑ Reductions in insulin dose by up to 49% ✅ Consistent ↓ in insulin use down to GFR of 30ml/min in whom glycosuric effect is minimal academic.oup.com/ndt/advance-...
2126
Pablo Angeles Tacchino @pabloangelest.bsky.social · 05/03/2025
Cool picture . cats claw is quite popular in Peru. #Nephmadness 2025
042
Reposted by Pablo Angeles Tacchino
Elliot Tapper @ebtapper.bsky.social · 04/03/2025
Spicy! Adding lasix to the management of hepatorenal syndrome might be ok if you bump the MAP with pressors @juancarlosqvelez.bsky.social doi.org/10.1016/j.ek... #nephsky #liversky
2258
Reposted by Pablo Angeles Tacchino
American Journal of Kidney Diseases @ajkd.bsky.social · 01/03/2025
#NephMadness 2025: The PodCrawl buff.ly/p3xR3cg Podcasts: - @thecurbsiders.bsky.social - Life as a Nephrology Professional @nkf-professionals.bsky.social - GN in Ten - @rheummadness.bsky.social - @freelyfiltered.bsky.social - Poison Lab - Nephron Segment - Kidney Chronicles
buff.ly
#NephMadness 2025: The PodCrawl
Submit your picks! |  @NephMadness |@nephmadness.bsky.social | NephMadness 2025 Over the next couple of weeks, NephMadness 2025 will be popping up on some great podcasts.  Keep your eyes and ears o…
01511
Pablo Angeles Tacchino @pabloangelest.bsky.social · 28/02/2025
Interesante
000
Pablo Angeles Tacchino @pabloangelest.bsky.social · 25/02/2025
journals.lww.com/kidney360/ab.... Great paper review Kidney 360
journals.lww.com
Acute Kidney Injury Associated with Novel Anti-Cancer... : Kidney360
ertain extent by systemic inflammatory toxicities affecting directly or indirectly the kidney. In the case of ICIs severe acute interstitial nephritis is the main adverse event and can lead to permane...
000